ArticleThe journal of allergy and clinical immunology. Global2025

Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI.

Agnes Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.